A Phase I, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4, in Participants With Advanced Solid Tumors
Latest Information Update: 10 Mar 2025
At a glance
- Drugs CS 2009 (Primary)
- Indications Adenocarcinoma; Carcinoma; Cervical cancer; Endometrial cancer; Gastric cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Renal cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors CStone Pharmaceuticals
Most Recent Events
- 04 Mar 2025 According to CStone Pharmaceuticals media release, company announced that the global multi-center Phase I clinical trial of CS2009, has successfully completed the dosing of the first patient without infusion reactions or other adverse events.
- 03 Mar 2025 According to CStone Pharmaceuticals media release, company announced that the first patient has been successfully dosed in the global multicenter Phase I clinical trial of its novel PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, with no infusion reactions or other adverse events observed. Also the company look forward to sharing additional clinical data that will further validate its safety and anti-tumor activity.
- 03 Mar 2025 Status changed from not yet recruiting to recruiting.